@article{c0d5d2d25e964f0e8a8cd9336cc566ad,
title = "Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer{\textquoteright}s disease",
abstract = "Objectives: Social dysfunction is one of the most common signs of major neuropsychiatric disorders. The Default Mode Network (DMN) is crucially implicated in both psychopathology and social dysfunction, although the transdiagnostic properties of social dysfunction remains unknown. As part of the pan-European PRISM (Psychiatric Ratings using Intermediate Stratified Markers) project, we explored cross-disorder impact of social dysfunction on DMN connectivity. Methods: We studied DMN intrinsic functional connectivity in relation to social dysfunction by applying Independent Component Analysis and Dual Regression on resting-state fMRI data, among schizophrenia (SZ; N=48), Alzheimer disease (AD; N=47) patients and healthy controls (HC; N=55). Social dysfunction was operationalised via the Social Functioning Scale (SFS) and De Jong-Gierveld Loneliness Scale (LON). Results: Both SFS and LON were independently associated with diminished DMN connectional integrity within rostromedial prefrontal DMN subterritories (pcorrected range=0.02–0.04). The combined effect of these indicators (Mean.SFS + LON) on diminished DMN connectivity was even more pronounced (both spatially and statistically), independent of diagnostic status, and not confounded by key clinical or sociodemographic effects, comprising large sections of rostromedial and dorsomedial prefrontal cortex (pcorrected =0.01). Conclusions: These findings pinpoint DMN connectional alterations as putative transdiagnostic endophenotypes for social dysfunction and could aid personalised care initiatives grounded in social behaviour.",
keywords = "Alzheimer{\textquoteright}s, DMN, Social dysfunction, schizophrenia, transdiagnostic",
author = "Saris, {Ilja M. J.} and Moji Aghajani and Reus, {Lianne M.} and Pieter-Jelle Visser and Yolande Pijnenburg and {van der Wee}, {Nic J. A.} and Bilderbeck, {Amy C.} and Andreea Raslescu and Asad Malik and Maarten Mennes and Sanne Koops and Celso Arrango and Ayuso-Mateos, {Jose Luis} and Dawson, {Gerard R.} and Hugh Marston and {PRISM consortium} and Kas, {Martien J.} and Penninx, {Brenda W. J. H.}",
note = "Funding Information: The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and EFPIA. This publication reflects only the author{\textquoteright}s views and neither the IMI 2JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein. Funding Information: The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and EFPIA. This publication reflects only the author{\textquoteright}s views and neither the IMI 2JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein. Funding Information: CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. MK has received (non-related) research funding from Novartis. BP has received (non-related) research funding from Jansen Research and Boehringer Ingelheim. ACB, AM, and GRD are fully employed by P1vital Ltd. GRD is an owner and shareholder of P1vital Ltd. and P1vital Products Ltd. IS, MA, LR, PV, YP, NW, AR, MM, SK JLAM and HM reported no financial interests or potential conflict of interests. Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2022",
doi = "https://doi.org/10.1080/15622975.2021.1966714",
language = "English",
volume = "23",
pages = "264--277",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "4",
}